Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas by Wanningen, Simone et al.
 
Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant
and Sensitive Medulloblastomas
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Nesterenko, Irina, Simone Wanningen, Tugba Bagci-Onder,
Maarten Anderegg, and Khalid Shah. 2012. Evaluating the effect
of therapeutic stem cells on TRAIL resistant and sensitive
medulloblastomas. PLoS ONE 7(11): e49219.
Published Version doi:10.1371/journal.pone.0049219
Accessed February 19, 2015 11:53:03 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579143
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAEvaluating the Effect of Therapeutic Stem Cells on TRAIL
Resistant and Sensitive Medulloblastomas
Irina Nesterenko
1,2., Simone Wanningen
1,2., Tugba Bagci-Onder
1,2, Maarten Anderegg
1,2,
Khalid Shah
1,2,3,4*
1Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America,
2Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 3Department of Neurology,
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 4Harvard Stem Cell Institute, Harvard University, Cambridge,
Massachusetts, United States of America
Abstract
Mesenchymal stem cells (MSC) are emerging as novel cell-based delivery agents; however, a thorough investigation
addressing their therapeutic potential in medulloblastomas (MB) has not been explored to date. In this study, we
engineered human MSC to express a potent and secretable variant of a tumor specific agent, tumor necrosis factor-
apoptosis-inducing ligand (S-TRAIL) and assessed the ability of MSC-S-TRAIL mediated MB killing alone or in combination
with a small molecule inhibitor of histone-deacetylase, MS-275, in TRAIL-sensitive and -resistant MB in vitro and in vivo.W e
show that TRAIL sensitivity/resistance correlates with the expression of its cognate death receptor (DR)5 and MSC-S-TRAIL
induces caspase-3 mediated apoptosis in TRAIL-sensitive MB lines. In TRAIL-resistant MB, we show upregulation of DR4/5
levels when pre-treated with MS-275 and a subsequent sensitization to MSC-S-TRAIL mediated apoptosis. Using
intracranially implanted MB and MSC lines engineered with different combinations of fluorescent and bioluminescent
proteins, we show that MSC-S-TRAIL has significant anti-tumor effects in mice bearing TRAIL-sensitive and MS-275 pre-
treated TRAIL-resistant MBs. To our knowledge, this is the first study that explores the use of human MSC as MB-targeting
therapeutic-vehicles in vivo in TRAIL-sensitive and resistant tumors, and has implications for developing effective therapies
for patients with medulloblastomas.
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Introduction
Medulloblastoma (MB) is a malignant brain tumor that
accounts for 30% of all pediatric brain tumors [1]. The peak
incidence of MB, which are classified as primitive neuroectoder-
mal tumors (PNETs) [1,2], in children is 7 years of age [3].
Current treatments for MB such as surgery, chemotherapy, and
cerebrospinal irradiation result in a 5-year survival prognosis of
about 60% [1]. However, the surviving patients experience
extreme side effects from radiation, including psychiatric disorders,
cognitive impairment, skeletal growth retardation, liver and kidney
toxicity, and endocrine dysfunctions [1]. Despite the improve-
ments made in the mode and delivery of radiation therapy, the
side effects due to its non-specific nature pose a serious concern in
the clinics [4]. Thus it is vital to find new and effective anti-MB
therapies that specifically target tumor cells and leave the normal
tissue unharmed.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a pro-apoptotic protein that targets tumor cells and
spares normal cells both in vitro and in vivo [5,6]. TRAIL induces
apoptosis by binding to its death domain-containing receptors
(DR) TRAIL-R1/DR4 and TRAIL-R2/DR5 on the cell surface
leading to a cascade of caspase activation and subsequent
execution of the apoptotic program [5,7–9]. While TRAIL has
been shown to induce apoptosis in few MB cell lines [10,11] its
efficacy in mouse models of MB has not been thoroughly tested.
Systemic administration of TRAIL in different mouse tumor
models has been rather ineffective because of its quick clearance
and requirement for repeated administration [12]. We and others
have previously shown that cell-based delivery of TRAIL is highly
efficacious in orthotopic brain tumor models due to the
tumoritropic properties of stem cells as well as the sustained
release of TRAIL on site of the tumors [13,14]. Human
mesenchymal stem cells (MSC) have been isolated from different
organs including brain, liver, kidney, lung, bone marrow, muscle,
thymus, pancreas, skin, adipose tissue, fetal tissues, umbilical cord,
Wharton’s jelly, and placenta [15–18], and have been used in
cancer therapy [14], The highest degree of lineage plasticity has
been imputed to bone marrow derived MSC, which are capable of
giving rise to virtually all cell types following implantation into
early blastocysts and are relatively easy to handle in vitro [19,20].
In this study we engineered human bone marrow derived MSC
engineered to release TRAIL.
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mediated apoptosis, with some tumors being TRAIL-resistant
[11,21]. The factors that determine TRAIL sensitivity remain only
partially understood, but several reports suggest that the levels of
DR4 and DR5 receptors constitute one important factor [22]. To
target a broad spectrum of tumors with TRAIL, it is critical to
assess combinatorial strategies that would sensitize TRAIL
resistant tumors for TRAIL induced apoptosis. Histone deacety-
lase inhibitors (HDACi) act through their modulation of the
epigenetic silencing [23], and recent reports have shown that
HDACis co-operate with other therapies, including TRAIL,
leading to the activation of cell death pathways in various cancer
models [23–27]. HDACis’ co-operation with TRAIL has been
shown to occur mainly through increased expression of death
receptors, particularly DR5 [7,24] and in some cases by increased
expression of DR4 [10,28]. In addition to its cooperation with
TRAIL, its reported brain access [29] makes it a potential
candidate for MB therapies, however characterization of its
efficacy in MB mouse models still remains to be explored.
In this study, we screened a cohort of MB lines for their
response to TRAIL mediated apoptosis and chose a TRAIL
sensitive and a resistant line to evaluate the therapeutic efficacy of
stem cell-mediated TRAIL. We created human mesenchymal
stem cells (hMSC) to express S-TRAIL and utilized optical
imaging-based reporters to assess the effect of MSC on MB growth
and the therapeutic efficacy of hMSC-S-TRAIL mediated MB
killing, alone or in combination with a small molecule activator of
DR4/5, MS-275, in vitro and in vivo.
Results
TRAIL Sensitivity of MB Cell Lines in vitro
We analyzed a panel of established and primary human MB cell
lines for their sensitivity to S-TRAIL induced apoptosis. DAOY,
D283, D458 and UW473 MB cell lines demonstrated resistance to
concentrations of S-TRAIL ranging from 0.5–2.0 mg/ml, whereas
R300, UW426 and R262 lines were sensitive to these concentra-
tions of TRAIL (Fig. 1a). Annexin V and PI staining on MB cells
revealed a greater shift into early (high Annexin, low PI) and late
apoptosis (high Annexin and high PI) in TRAIL sensitive lines
(UW426 and R262) as compared to the TRAIL semi-resistant and
resistant lines, thus further confirming the varying degree of
sensitivity to TRAIL mediated apoptosis (Fig. 1b). We then chose
the TRAIL-sensitive cell line, UW426, and the TRAIL-resistant
cell line, DAOY, for further investigation. Flow cytometry analysis
showed that DAOY cells had low endogenous levels of DR4 and
DR5 (Figs. 1c and 1e), whereas UW426 cells had DR4 levels similar
to that of DAOY cells, but showed approximately 10 fold higher
level of endogenous DR5 (Figs. 1d and 1f). These results were
substantiated by assessment of endogenous DR4 and DR5
promoter activity using DAOY and UW426 cells transduced with
DR4/DR5 promoter-Fluc vectors (Fig. 1g). Semi-quantitative RT-
PCR analysis showed a higher DR5 expression in UW426 (band
intensity value:143) cells as compared to DAOY (band intensity
value: 118) cells and no differences in DR4 expression (Fig. 1h).
These results revealed that MB cells have varying sensitivity to
TRAIL mediated apoptosis and that the sensitivity of our chosen
lines correlates with endogenous levels of the TRAIL receptors,
particularly DR5.
UW426 Cells are Sensitive to Stem Cell-delivered TRAIL
To first test whether human mesenchymal stem cells (hMSCs)
would influence UW426 cell growth, we performed both in vitro
co-culture and in vivo studies. UW426 cells engineered to express
Fluc-mCherry (Fig. S1a) were co-cultured with increasing numbers
of hMSCs engineered to express GFP (Fig. S2a). Luciferase
activity, indicating the UW426-Fluc-mCherry cell viability showed
that hMSCs had no influence on the growth of UW426 cells
(Fig. 2a). To investigate the effect of hMSC-delivered TRAIL on
UW426 cells, hMSC were engineered to express S-TRAIL by
transducing hMSC with LV-S-TRAIL. Engineered hMSC-S-
TRAIL secreted S-TRAIL (300 ng/mL/10
6 cells) in the culture
medium (Figs. S2b and S2c). To test the efficacy of hMSC-S-
TRAIL on UW426 MBs, UW426-Fluc-mCherry cells were co-
cultured with increasing numbers of hMSC-S-TRAIL. A signif-
icant decrease in UW426-Fluc-mCherry cell viability was seen in
UW426-Fluc-mCherry/hMSC-S-TRAIL co-cultures at even the
lowest ratio of hMSC-S-TRAIL to UW426 (Fig. 2b). These results
were substantiated by luciferase measurements taken at 0, 2, and 5
days of co-culture of UW426-Fluc-mCherry alone or with hMSC-
GFP or hMSC-S-TRAIL (Fig. 2c). In vivo, intracranial implanta-
tion of hMSC-GFP and UW426-Fluc-mCherry tumor cells did
not affect UW426-Fluc-mCherry growth over time when com-
pared to UW426-Fluc-mCherry cells implanted alone (Fig. 2d),
butimplantation of UW426-Fluc-mCherry with hMSC-S-TRAIL
showed significant changes in tumor growth as compared to
controls (Fig. 2e). Immunohistochemistry performed on brain
sections revealed the presence of hMSCs within the tumors
(Figs. 2k and 2o) and a significantly increased number of cleaved
caspase-3 in the hMSC-S-TRAIL treated groups as compared to
hMSC-GFP treated or untreated groups (Figs. 2h,l,p,r). These
studies reveal that S-TRAIL-secreting MSCs induce apoptosis
through caspase activation in UW426 tumors and have a
significant effect on the growth of MBs in vitro and in vivo.
MS-275 and Radiation Induce TRAIL Sensitization in
DAOY Cells by Up-regulation of DR5
MS-275 and radiation-therapy (iRad) have been shown to
sensitize cancer cells to TRAIL treatment via different pathways
[9,30,31]. To determine whether this can be translated into
TRAIL-resistant MB cell lines, we performed experiments on the
TRAIL-resistant DAOY line engineered to express Fluc-mCherry
(Fig. S1b), pre-treated with either HDAC inhibitor (MS-275; 0.625
or 1.25 mM) or single dose of irradiation (8Gy). Cell viability
analysis demonstrated that S-TRAIL, MS-275, and radiation by
themselves did not induce cell death in DAOY cells, however a
significant dose-dependent decrease in cell viability was seen when
DAOY- Fluc-mCherry cells were pre-treated with MS-275 and
subsequently treated with S-TRAIL (Fig. 3a). Similar changes
were observed when DAOY cells were pre-treated with 8Gy of
irradiation and subsequently treated with S-TRAIL (Fig. 3a). Flow
cytometry analysis indicated that both MS-275 and irradiation
resulted in upregulation of TRAIL death receptors (DR)4 and
mainly the DR5 levels in both treatment types as compared to
endogenous DR5 levels in DAOY cells (Figs. 3b–e). In vitro caspase-
3/7 analysis on DAOY cells treated with MS-275 or iRad and
TRAIL showed a significant increase in caspase-3/7 levels in co-
treated cells (approximately 6-fold increase with MS-275 and
TRAIL; and 3 fold increase with iRad and TRAIL) as compared
to control single treatments (Fig. 3f). Western blot analysis of
cleaved PARP protein on single- and co-treated DAOY cells with
MS-275, iRad, and S-TRAIL showed an increase in cleaved
PARP in the co-treatment groups, indicating the activation of the
apoptosis pathway (Fig. 3g). When these experiments were
performed on TRAIL-sensitive UW426 cells, an additive effect
was observed in cells that were pre-treated with MS-275 or with a
single dose of radiation, as evidenced by upregulation of DR4,
DR5, and PARP cleavage (Fig. S3). These results reveal that
Therapeutic Stem Cells to Treat Medulloblastomas
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MS-275 or radiation sensitizes them to TRAIL by upregulating
the endogenous TRAIL receptor DR5 and activating the TRAIL-
induced apoptosis pathway.
MS-275 Sensitizes TRAIL-resistant DAOY Cells to Stem
Cell-delivered TRAIL in vivo
As the non-specificity of radiation treatment and the subsequent
damage to healthy tissue in patients are a serious concern in the
clinics [4], we utilized MS-275 for further evaluation. To assess the
combined effect of MS-275 and hMSC-S-TRAIL, we performed
both in vitro co-culture and in vivo studies on TRAIL-resistant
DAOY-Fluc-mCherry MB cells. hMSC-GFP or hMSC-S-TRAIL
co-cultured with DAOY-Fluc-mCherry in different ratios showed
no significant difference in their effect on the growth of DAOY
cells, although the presence of hMSCs resulted in approximately
20% decrease in DAOY cell viability in DAOY cell/hMSC co-
cultures as compared to DAOY cells that were cultured alone
(Fig. 4a). In vivo, intracranial implantation of DAOY-Fluc-
mCherry with hMSC-GFP or hMSC-S-TRAIL demonstrated
no difference in tumor growth on 1, 5, and 20 days after
implantation (Fig. 4b). Next, DAOY-Fluc-mCherry cells were
treated with MS-275 and co-cultured with hMSC-GFP or hMSC-
S-TRAIL. A significant decrease in cell viability was seen when
DAOY-Fluc-mCherry cells were treated with MS-275 and co-
cultured with hMSC-S-TRAIL as compared to each single
treatment (Fig. 4c). Similar results were obtained when MS-275
and S-TRAIL combination was tested in culture on another
TRAIL-resistant (UW473) medulloblastoma line engineered to
express mCherry-Fluc (Fig. S4) Additionally, when MS-275 and S-
TRAIL combination was tested on a TRAIL-sensitive (R262)
medulloblastoma line engineered to express mCherry-Fluc, a
significant decrease in cell viability was seen when cells were
treated with MS-275 and co-cultured with hMSC-S-TRAIL as
Figure 1. TRAIL sensitivity or resistance in MBs is correlated with DR4 and DR5 levels cells. (a) Plot showing the cell viability analysis on
different MB cell lines treated with S-TRAIL. (b) FACS scatter plots showing Annexin V and PI staining on MB cell lines after treatment with 0 or
100 ng/mL S-TRAIL. (c–f) FACS histogram plots showing endogenous levels of DR4 (c–d) and DR5 (e–f) on DAOY (TRAIL-resistant) and UW426 (TRAIL-
sensitive) cells (grey peak=isotype control). (g) Plot showing the levels of DR4 and DR5 in DAOY and UW426 cells transduced with LV-pDR4-Fluc and
LV-pDR5-Fluc. (h) RT-PCR analysis showing endogenous levels of DR4 and DR5 mRNA expression in DAOY and UW426 cells. GAPDH is used as control.
* denotes p,0.05 in the comparison of each treatment to controls, student’s t-test.
doi:10.1371/journal.pone.0049219.g001
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implantation of MS-275 treated DAOY- Fluc-mCherry cells with
hMSC-S-TRAIL showed significant differences in tumor growth
as compared to tumors treated with hMSC-GFP. Further analysis
revealed that the combination of MS-275 and hMSC-S-TRAIL
decreased tumor growth by approximately 90% (Fig. 4d). Immu-
nohistochemistry performed on brain sections revealed the
presence of hMSCs within the tumors (Figs. 4e,f,i,j) and
significantly more cells expressing cleaved caspase-3 in the MS-
275 and hMSC-S-TRAIL double-treated groups than MS-275
and hMSC-GFP treated or untreated groups (Figs. 4g,h,k,l,m).
These results demonstrate that MS-275 sensitizes TRAIL-resistant
DAOY cells to hMSC-delivered TRAIL in vitro. In vivo, MS-275
and hMSC-S-TRAIL combination therapy is effective at eradi-
cating TRAIL-resistant DAOY tumor cells.
Discussion
In this study we engineered human MSC to express S-TRAIL
and utilized optical imaging-based reporters to assess the ability of
hMSC-S-TRAIL mediated MB killing, alone in TRAIL sensitive
MB, or in combination with an HDAC inhibitor, MS-275, in
TRAIL resistant MB, in vitro and in vivo. We show that TRAIL
sensitivity/resistance correlates with the expression of cognate
death receptors (DR)4 and especially DR5, and that hMSC-S-
TRAIL induces caspase-3 mediated apoptosis in both TRAIL
sensitive and resistant lines pre-treated with an HDAC inhibitor
(MS-275) in vitro and in vivo.
TRAIL is known to be effective as a tumor-selective cytotoxic
agent and signals via two pro-apoptotic death receptors, DR4
and DR5, inducing a caspase-dependent apoptotic cascade in
tumor cells [5,14,32–34]. However, because of its short
biological half-life and limited delivery across the blood-brain
barrier, most promising studies using purified TRAIL protein
lack applicability [12,35,36], necessitating development of a cell-
based delivery method for intracerebral pathologies. As stem
cells are known to have tropism for tumor cells in the brain
[13,33,37–40], stem cell-mediated therapy is emerging as a
strategy to effectively deliver molecular therapies, like IFN-beta
[41], IL-2 [40,42], cytosine deaminase [43], and oncolytic
adenovirus [44], in the brain. Multiple potential sources for
clinically useful stem and progenitor cells have been identified,
including autologous and allogeneic embryonic cells and fetal
and adult somatic cells from mesenchymal, neural and adipose
tissues [14]. Mesenchymal stem cells (MSCs) harvested from
bone marrow are relatively easy to obtain, highly proliferative,
allow for autologous transplantation, and in contrast to embryo-
derived stem cells, pose hardly any ethical problems, making
them an attractive option for a cell-based therapy for MB.
Because of their high amphotrophic receptor levels, MSCs are
readily transducible with integrating vectors, leading to stable
transgene expression in vitro and in vivo [14,45]. Our results
reveal that hMSCs themselves have no effect on growth of
Figure 2. UW426 MB cells are sensitive to stem cell-delivered TRAIL. (a) Plot showing the viability of UW426-Fluc-mCherry MB cells co-
cultured with hMSC-GFP cells with different ratios of hMSC to MB cells. (b) Plot showing the viability of UW426-Fluc-mCherry MB cells co-cultured
with hMSC-S-TRAIL cells with different ratios of hMSC to MB cells. (c) Plot showing the viability of UW426-Fluc-mCherry cells on 0, 2, 5 days of co-
culture with hMSC-GFP or hMSC-S-TRAIL cells. Representative pictures showing UW426 (red) co-cultured with hMSC (green) obtained on day 5. (d)
Plot showing Fluc bioluminescence activity of intra-parenchymally implanted mice with UW426-Fluc-mCherry cells with or without hMSC-GFP on
days 2, 3, and 5 post-implantation. Representative images are shown from one mouse per group on day 3. (e) Fluc bioluminescence activities of intra-
parenchymally implanted UW426-Fluc-mCherry cells with hMSC-GFP or with hMSC-S-TRAIL at 2, 3 and 5 days post-implantation. Representative
images are shown from one mouse per group on day 3. (f–q) Photomicrographs and immunohistochemistry of brain sections on day 2 from mice
bearing UW426-Fluc-mCherry tumors alone or with hMSC expressing either TRAIL and GFP or GFP. (r) Plot showing the number of cleaved caspase-3-
positive UW426 cells in tumors without hMSC or with hMSC-GFP or hMSC-S-TRAIL (Original magnification: c,610; f–q,620.). * denotes p,0.05 in the
comparison of each treatment to controls, student’s t-test.
doi:10.1371/journal.pone.0049219.g002
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therapeutic delivery. When engineered to express S-TRAIL,
hMSCs lead to a significant reduction of tumor growth of
TRAIL-sensitive MB lines as shown in MSC-tumor cell co-
cultures as well as in in vivo MB models, indicating that hMSC-
S-TRAIL therapy is highly efficient in TRAIL-sensitive MBs.
Such a cell-based therapeutic delivery system offers continuous
and concentrated local delivery of secretable molecules like
TRAIL, thus reducing non-selective targeting and allowing
higher treatment efficiency as compared to systemically-deliv-
ered therapies.
Although TRAIL has been shown to be effective for some
brain tumor types [5–12,21] and UW426-type MB in this study,
it is well known that established tumor lines have varying
resistance/sensitivity with about 50% of lines being resistant to
TRAIL [46,47]. The silencing of TRAIL death receptor (DR)
expression, and/or upregulation of TRAIL decoy receptors is
one of the underlying mechanisms of TRAIL resistance in
tumor cells [46]. Numerous studies by us and others have
shown the potential of sensitizing TRAIL-resistant tumor cell
lines by combining TRAIL with other chemotherapeutic agents
that upregulate DR4/5 levels on cells or simultaneously activate
intracellular signaling cascades [12,48–53]. Histone deacetylase
inhibitor MS-275, has been shown to sensitize MB cells to
TRAIL by reactivating death receptor-4 (DR4), and upregulat-
ing apoptotic caspases 3, 8, and 9, all of which are major
players in the pro-apoptotic pathway [10,28,54]. Our investiga-
tion on the effect of TRAIL on various MB lines revealed that
endogenous levels of DR5 may be a good predictor for
resistance or sensitivity to TRAIL; lines with low expression,
such as the proven TRAIL-resistant DAOY cell line, would be
good candidates for combination therapy with MS-275. Our
results confirmed that treating DAOY cells with MS-275 as part
of a combination therapy with S-TRAIL sensitizes them to
TRAIL-mediated apoptosis, as evidenced by increases in several
members of the apoptosis cascade, cleaved PARP and Caspase-
Figure 3. MS-275 and irradiation (iRad) treatment sensitize TRAIL resistant DAOY cells to S-TRAIL mediated apoptosis. (a) Plot
showing the viability of DAOY cells treated with 0.5 mg/ml TRAIL for 24 hours, MS-275 (0.625 mM; 1.250 mM) for 48 hours, iRad (8Gy) for 72 hours and
combinations with S-TRAIL. (b–e) FACS analysis of DR4 (b and c) and DR5 (d and e) DAOY cells treated with 8Gy iRad (light blue in b,c) and 1.25 mM
MS-275 (light blue in d,e) (blue: isotype control, grey: untreated). (f) Caspase 3&7 analysis in DAOY cells treated with 0,5 mg/ml TRAIL (24 hours),
1.25 mM MS-275 (48 hours), 8Gy iRad (72 hours) and combinations of MS-275 and iRad with TRAIL. (g) Western blot analysis showing cleaved PARP
and a-tubulin of DAOY cells treated with TRAIL, MS-275, iRad and combinations as described above. * denotes p,0.05 in the comparison of each
treatment to controls, student’s t-test.
doi:10.1371/journal.pone.0049219.g003
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treatment group suggests that MS-275 as a monotherapy might
cause cytostatic response in vivo, when administered systemically.
Therefore, it will be of major interest to test the effect of
systemically-delivered HDACis in our in vivo MB models.
Although the MB lines used in this study allow a thorough
investigation of the response to TRAIL mediated apoptosis
in vitro, the tumorigenic potential of some MB lines in vivo is
limited. Our results show that TRAIL sensitive line UW426
does not readily form tumors after their intracranial implanta-
tion in vivo therefore limiting the duration of our in vivo
experiments This is in line with the previous studies that have
shown that mice orthotopically injected with UW426-GFP lines
exhibited limited hyperplasia at injection sites [55]. However
modifying lines with pro-tumorigenic molecules like Myc was
shown to allow growth of intracranial UW426 line. High Myc
expression in both UW228 and UW426 cells lines had potent
in vivo oncogenic effects [55]. To our advantage, the TRAIL-
resistant DAOY line engineered with lentiviral vectors main-
tained its tumorigenicity upon implantation, allowing us for
long-term assessment of the hMSC-S-TRAIL effect, which
would otherwise not be possible to demonstrate MS-275
mediated TRAIL-sensitization. While our current studies might
serve as a good preclinical assessment of MSC-based therapeu-
tics for MBs in vivo, it will be very important to expand these
studies into additional in vivo models of MB including genetically
engineered mouse models that recapitulate MB pathology
[30,31].
In conclusion, our studies reveal the therapeutic efficacy of
engineered hMSCs in a xenograft mouse model of MB for a
TRAIL-sensitive line, as well as the sensitizing effect of HDAC
inhibitor MS-275 to stem cell-delivered TRAIL on a TRAIL-
resistant line. This is the first study, which explores the use of
human MSC as a MB-targeting therapeutic vehicle in vivo in
TRAIL-resistant and -sensitive tumors and should have implica-
tions for developing effective therapies for patients with medullo-
blastomas. In the future, we envision a resection model where the
tumor mass is removed and the patient’s own therapeutically
engineered MSCs are administered locally at the time of resection.
The excised tumors can be profiled for their response to TRAIL
and MS-275 or irradiation can be administered accordingly. Using
this study as a template, advances can be made in the way stem
cells can be clinically used in combination with another therapy
for patients with MB tumors.
Figure 4. MS-275 treatment sensitizes TRAIL resistant DAOY cells to hMSC-S-TRAIL in vivo. (a) Plot showing the viability of DAOY-Fluc-
mCherry MB cells co-cultured with hMSC-GFP or hMSC-S-TRAIL with different ratios of MB to hMSC cells. (b) Fluc bioluminescence intensities of
intraparenchymally implanted mice with DAOY-Fluc-mCherry human MB cells mixed with either hMSC-GFP or hMSC-S-TRAIL on Days 1, 5 and 20.
Representative images of mice for each group are shown. (c) Plot showing the viability of DAOY-Fluc-mCherry MB cells pre-treated with increasing
concentrations of MS-275 and incubated with hMSC-GFP or hMSC-S-TRAIL. (d) Fluc bioluminescence intensities of intraparenchymally implanted mice
with MS-275 treated DAOY-Fluc-mCherry human MB cells mixed with either hMSC-GFP or hMSC-S-TRAIL on Days 1 and 5. Representative images of
mice for each group are shown. (e–l) Photomicrographs and immunohistochemistry of brain sections from mice bearing DAOY tumors treated with
MS-275 and with hMSC-GFP or hMSC-S-TRAIL: DAOY cells expressing mCherry (e,i); hMSC-GFP (f) and hMSC-S-TRAIL (j) cells expressing GFP; Cleaved
caspase-3 staining (g,k). Merged image (h,l; Red, mCherry expression; green, GFP expression; blue, cleaved caspase-3 staining). (m) Plot shows the
number of cleaved caspase-3-positive DAOY cells in MS-275-pretreated tumors with hMSC-GFP or hMSC-S-TRAIL. (Original magnification: e–l,620.). *
denotes p,0.05 in the comparison of each treatment to controls, student’s t-test.
doi:10.1371/journal.pone.0049219.g004
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Cell Culture and Lentiviral Transduction
Medulloblastoma cell lines (DAOY, R300, UW426, R262,
UW473, D283 and D458) were kindly provided by Jae-Yoon Cho
[56] (Department of Neurology/Neuro-oncology at Children’s
Hospital, Boston, MA). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; GIBCO) supplemented with 10% Fetal
calf serum (Valley Biomedical inc.), 1% Penicillin/Streptomycin
(Invitrogen,) 2% sodium bicarbonate (Lonza), 1% nonessential
amino acids (Cellgro), 1% sodium pyruvate (Cellgro), and 1% L-
glutamine (GIBCO). Human bone marrow derived mesenchymal
stem cells (hMSC; Kindly provided by Dr. Prockop, Tulane
University, New Orleans) were cultured in Alpha-MEM (GIBCO)
supplemented with 20% fetal calf serum, 1% L-glutamine, and 1%
penicillin/streptomycin. LV-Fluc-mCherry, LV-S-TRAIL and
LV-GFP lentiviral constructs were packaged in 293T cells and
UW426-Fluc-mCherry, DAOY-Fluc-mCherry, R262-Fluc-
mCherry, UW473-Fluc-mCherry, hMSC-S-TRAIL and hMSC-
GFP cell lines were generated through lentiviral transduction as
described previously [57].
Cell Viability and Caspase 3/7 Assay
MB cells were incubated for 6 or 24 hours with different
concentrations of S-TRAIL (0–2.5 mg/ml) as previously described
[13]. For assessment of MS-275 effect, MB cells were incubated for
48 hours with 0.650 mM or 1.25 mM of MS-275 (Cayman
Chemicals). For assessment of irradiation effect, MB cells were
irradiated (8 Gy; using Mark I 137-Cesium irradiator) and for
combination experiments, MB cells were first treated with MS-275
(for 48 hours) or iRad (incubated for 72 hours), then treated with
S-TRAIL. Cell viability was measured by a quantitative lumines-
cence assays using an ATP-dependent luminescent reagent
(CellTiter-Glo, Promega), according to the manufacturer’s in-
structions. Caspase 3/7 activity was determined with a caspase 3/
7-activatable DEVD-aminoluciferin (Caspase-Glo, Promega). Lu-
minescence was measured with a luminometer (Promega) at 0.20
seconds/well. Cell viability of Fluc-expressing cells was measured
as a function of luciferase activity of remaining viable cells. Cells
were incubated with 0.1 mg/ml D-luciferin (Caliper Life Sciences,
inc.) and luminescence was measured with a luminometer at 0.5
seconds/well.
DR4/5 Promoter Reporter Assay
The DR4 or DR5 promoter reporter vectors were kindly
provided by Dr. Shi-Yong Sun (Emory University, Atlanta, GA).
DR4-Fluc and DR5-Fluc promoters were PCR amplified and sub-
cloned into CSCGW lentiviral vector as described elsewhere [58].
DAOY and UW426 cells were transduced in a 96-well format
(5610
3 cells/well) with LV-DR4-Fluc and LV-DR5-Fluc. The
DR4 or DR5 transcription levels were measured using 1 mg/ml
luciferin and normalized to cell viability as determined by parallel
viability assays. Each experiment was performed in triplicates.
Flow Cytometric Analysis
For Annexin V and Propidium Iodide staining, DAOY, D283,
D458, R262, R300, UW426, and UW473 cell lines were treated
with 100 ng/mL S-TRAIL for 12 hours. Cells were harvested and
0.5610
6 cells/sample were stained with an Annexin V and
Propidium Iodide kit (Vybrant Apoptosis Assay Kit #2, Invitro-
gen) and prepared for flow cytometry according manufacturer’s
instructions. Flow cytometry was performed on a BD FACS Aria
Instrument and the data analyzed using DiVa and FlowJo (BD
BioScience). For DR4 and DR5 analysis, DAOY and UW426 cells
were treated with 1.25 mM MS-275 for 48 hours, or irradiated
with 8Gy and incubated for 72 hours. Cells were harvested and
0.5610
6 cells/sample were stained with mouse anti-human DR4-
FITC (Abcam), mouse anti-human DR5-PE (R&D Systems inc.),
mouse anti-human IgG1-FITC control antibody (MACS Miltenyi
Biotech) or mouse anti-human IgG2B-PE control antibody (R&D
systems inc.) and prepared for flow cytometry according manu-
facturer’s instructions. Flow cytometry was performed on a BD
FACS Calibur Instrument and the data analyzed using CellQuest
Pro (BD BioScience).
RT-PCR
mRNA was extracted using PureLink RNA Kit (Ambion) and
cDNA was synthesized with Superscript VILO cDNA synthesis kit
(Invitrogen). Semi-quantitative RT-PCR was performed with 25
cycles using the following primer pairs: DR4: forward, 59-
AGAGAGAAGTCCCTGCACCA -39; reverse, 59- GTCA
CTCCAGGGCGTACAAT -3. DR5: forward, 59- CAC-
CAGGTGTGATTCAGGTG -39; reverse, 59- TACGGCTG
CAACTGTGACTC -3. GAPDH: forward, 59-CATGAGAAG-
TATGACAACAGCCT-39; reverse, 59-AGTC CTTCCACGA-
TACCAAAGT-39.
Western Blotting
Whole cell lysates were extracted from DAOY and UW426 cells
that were treated with MS-275, iRad, TRAIL or combinations
MS-275+TRAIL and iRad+TRAIL as described above. Lysates
were resolved by SDS-PAGE, transferred to nitrocellulose, and
probed with antibodies against cleaved PARP (Cell Signaling
Technology), and a-tubulin (Sigma).
Medulloblastoma and hMSC Co-culture Experiments and
Cell Viability Assays
UW426-Fluc-mCherry cells and R262-Fluc-mCherry were
plated with varying numbers of hMSC-GFP or hMSC-TRAIL
(1000–5000/well) in a 96-well plate (Costar), and incubated in
hMSC medium for 48 hours; time course experiments were
conducted at a single ratio, 1:1, and viability was measured at days
1, 2, and 5 by luciferase based assay. For sensitization experiments,
DAOY-Fluc-mCherry and UW473-Fluc-mCherry cells were
plated in 96-wells, treated for 24 hours with 1.25 or 2.5 mMo f
MS-275 (Cayman Chemicals) followed by addition of hMSC-GFP
or hMSC-S-TRAIL cells in hMSC medium. Cell viability was
measured as described above.
Intracranial Cell Implantations and in vivo Imaging
To investigate the efficacy of hMSC or hMSC-S-TRAIL on MB
cells, DAOY-Fluc-mCherry, UW426-Fluc-mCherry, hMSC-GFP,
and hMSC-S-TRAIL cells were harvested at 80–90% confluency
and implanted in the following experimental groups: DAOY-Fluc-
mCherry with hMSC-GFP, DAOY-Fluc-mCherry with hMSC-S-
TRAIL, UW426-Fluc-mCherry alone, UW426-Fluc-mCherry
with hMSC-GFP, and UW426-Fluc-mCherry with hMSC-S-
TRAIL (n=5/group). These combinations were implanted
stereotactically into nude mice brains (4610
5 of each cell type in
5–6 ml of DMEM, in the following co-ordinates: 2.2 mm lateral
from bregma, on the cranial suture, 2.5 mm ventral from dura).
Mice were imaged for Fluc activity on 1, 2, 5 and 20 days after
implantations as described previously [13]. All in vivo procedures
were approved by the Subcommittee on Research Animal Care at
Massachusetts General Hospital.
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Immediately following the last imaging session in mice
implanted with control or hMSC-S-TRAIL, mice were perfused,
brains were removed, and 30 mM brain sections were immuno-
stained with antibodies against cleaved caspase-3 (Cell Signaling
Technology), and detected by Alexa 647 labeled secondary
antibodies (Cell Signaling Technology). GFP-expressing hMSC,
mCherry-expressing MB cells, and cleaved caspase-3 immuno-
staining were visualized by confocal microscopy as described
previously [12].
Statistical Analysis
Data were analyzed by Student t-test when comparing 2 groups.
Data were plotted as mean6SEM and differences were considered
significant at P,0.05.
Supporting Information
Figure S1 Engineered MB lines. (a–b) Graphs showing
correlation between UW426-Fluc-mCherry (a) and DAOY-Fluc-
mCherry (b) cell numbers and Fluc signal within the ranges tested.
Representative photomicrographs of the lines growing in culture
are shown (Original magnification: a–b, 610.)
(TIF)
Figure S2 Engineered hMSC lines. (a–b) Photomicrographs
showing hMSC-GFP and hMSC-S-TRAIL in culture (Original
magnification: a–b, 610.). (c) TRAIL ELISA showing the
concentration of S-TRAIL released by hMSC-S-TRAIL.
(TIF)
Figure S3 HDACi (MS-275) and irradiation (iRad) has
an additive effect to TRAIL in TRAIL sensitive UW426
cells. (a) Viability analysis on UW426 cells that are treated with
0.5 mg/ml TRAIL for 24 hours, MS-275 (0.625 mM; 1.250 uM)
for 48 hours, iRad (8Gy) for 72 hours and combinations with
TRAIL. (b–e) FACS analysis of DR4 (b and d) and DR5 (c and e)
stained UW426 cells treated with 8Gy iRad (light blue in b,c) and
1.25 mM MS-275 (light blue in d,e) (blue: isotype control, dark
blue: untreated). (f) Caspase 3&7 analysis in UW426 cells treated
with 0.5 mg/ml TRAIL (24 hours), 1.25 mM MS-275 (48 hours),
8Gy iRad (72 hours) and combinations of MS-275 and iRad with
TRAIL. (g) Western blot analysis showing cleaved PARP and a-
tubulin of UW426 cells treated with TRAIL, MS-275, iRad and
combinations. * denotes p,0.05 in the comparison of each
treatment to controls, student’s t-test.
(TIF)
Figure S4 R262 cells are sensitive to hMSC-S-TRAIL
and MS-275 treatment sensitizes TRAIL-resistant
UW473 cells to hMSC-S-TRAIL in vitro. (a–b) R262 and
UW473 were engineered to express mCherry-Fluc. Graphs
showing correlation between R262-Fluc-mCherry (a) and
UW473-Fluc-mCherry (b) cell numbers and Fluc signal within
the ranges tested. Representative photomicrographs of the
engineered lines in culture are shown. (c–d) Plot showing the
viability of R262-Fluc-mCherry (c) and UW473-Fluc-mCherry (d)
MB cells pre-treated with 2.5 mM MS-275 and incubated alone or
with hMSC-GFP or hMSC-S-TRAIL. (Original magnification: a–
b, 610).
(TIF)
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